151751-Najiba-Chargi

290 CHAPTER 15 14. Daly LE, Ní Bhuachalla ÉB, Power DG, Cushen SJ, James K, Ryan AM. Loss of skel - etal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcope- nia Muscle . 2018;9(2):315-325. doi:10.1002/ jcsm.12267 15. Kurk SA, Peeters PHM, Dorresteijn B, et al. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. Cancer Med . 2020;9(3):1033-1043. doi:10.1002/cam4.2787 16. De Nardi P, Salandini M, Chiari D, et al. Changes in body composition during neo- adjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study. Curr Probl Cancer . 2020;44(2):100510. doi:10.1016/j.currproblcancer.2019.100510 17. Basile D, Corvaja C, Caccialanza R, Aprile G. Sarcopenia: Looking to muscle mass to better manage pancreatic cancer patients. Curr Opin Support Palliat Care . 2019;13(4):279-285. doi:10.1097/ SPC.0000000000000455 18. Stone L, Olson B, Mowery A, et al. Associ - ation between Sarcopenia and Mortality in Patients Undergoing Surgical Excision of Head and Neck Cancer. In: JAMA Otolar- yngology - Head and Neck Surgery . Vol 145. American Medical Association; 2019:647- 654. doi:10.1001/jamaoto.2019.1185 19. Chargi N, Bril SI, Swartz JE, Wegner I, Wil - lems SW, de Bree R. Skeletal muscle mass is an imaging biomarker for decreased sur- vival in patients with oropharyngeal squa- mous cell carcinoma. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104519 20. Ansari E, Chargi N, van Gemert JTM, et al. Low skeletal muscle mass is a strong pre- dictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104530 21. Chargi N, Bril SI, Emmelot-Vonk MH, de Bree R. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Oto-Rhi- no-Laryngology . 2019;276(5):1475-1486. doi:10.1007/s00405-019-05361-4 22. Huang X, Ma J, Li L, Zhu X dong. Severe muscle loss during radical chemoradiother- apy for non-metastatic nasopharyngeal carcinoma predicts poor survival. Cancer Med . 2019;8(15):6604-6613. doi:10.1002/ cam4.2538 23. Mitsiopoulos N, Baumgartner RN, Heyms - field SB, et al. Cadaver Validation of Skeletal MuscleMeasurement byMagnetic Resonance Imaging and Computerized Tomography .; 1998. http://www.jap.org. 24. Chargi N, Ansari E, Huiskamp LFJ, Bol G, de Bree R. Agreement between skeletal muscle mass measurements using computed to- mography imaging andmagnetic resonance imaging in head and neck cancer patients. Oral Oncol . 2019;99:104341. doi:10.1016/j. oraloncology.2019.06.022 25. Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT im - aging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol . 2016;62:28-33. doi:10.1016/j.oraloncolo - gy.2016.09.006 26. Brown JC, Caan BJ, Meyerhardt JA, et al. The deterioration of muscle mass and ra- diodensity is prognostic of poor survival in stage I-III colorectal cancer: a popula- tion-based cohort study (C-SCANS). J Ca- chexia Sarcopenia Muscle . 2018;9(4):664- 672. doi:10.1002/jcsm.12305 27. Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmeta - static Colorectal Cancer Results From the C SCANS Study Supplemental content. JAMA Oncol . 2017;3(12):172319. doi:10.1001/jama - oncol.2017.2319